세계의 다중 암 조기 발견 시장 - 업계 분석, 규모, 점유율, 성장, 동향, 지역별 전망 및 예측(2023-2030년) : 유형별, 최종 용도별, 지역별, 기업별
Multi-Cancer Early Detection Market - Global Multi-cancer Early Detection Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - (By Type Coverage, By End User Coverage, By Geographic Coverage and By Company)
상품코드:1389857
리서치사:Fairfield Market Research
발행일:2023년 11월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 다중 암 조기 발견(MCED) 시장 규모는 크게 확대되는 기세이며, 2023년부터 2030년까지 CAGR 16.3%가 될 것으로 예측되고 있습니다. 이 시장은 2022년 약 8억 9,000만 달러에서 2030년 말까지 약 25억 달러까지 확대될 것으로 예측됩니다.
MCED 시장은 암 이환율 증가나 암의 조기 발견에 중점을 둔 정부의 대처 등 요인별로 확대될 것으로 보입니다. 다양한 암의 징후를 정확하고 동시에 검색할 수 있는 검사의 개척이 시장 성장을 가속할 것으로 예측됩니다. 이러한 검사는 많은 유형의 암에 대한 효율적인 스크리닝 접근법의 부족을 해결합니다.
환자의 생존율을 높이고 치료비를 삭감하기 위한 조기암 발견의 이점에 대한 인식 증가가 시장의 가능성을 뒷받침하고 있습니다. 2022년에는 유전자 패널 카테고리가 MCED 시장을 독점했습니다. 유전자 패널은 다양한 악성 종양과 관련된 여러 유전자의 표적 연구를 제공하여 정확한 위험 평가와 조기 발견을 가능하게 합니다.
이 보고서는 세계의 다중 암 조기 발견 시장에 대해 조사했으며, 시장 개요와 함께 유형별, 최종 용도별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공합니다.
목차
제1장 주요 요약
제2장 시장 개요
시장 정의 및 세분화
시장 역학
밸류체인 분석
Porter's Five Forces 분석
COVID-19의 영향 분석
우크라이나와 러시아의 분쟁의 영향
경제 개요
PESTLE 분석
제3장 세계의 다중 암 조기 발견 시장 전망(2018-2030년)
세계의 다중 암 조기 발견 시장 전망 : 유형별, 금액별(10억 달러)(2018-2030년)
세계의 다중 암 조기 발견 시장 전망 : 최종 용도별, 금액(10억 달러)(2018-2030년)
세계의 다중 암 조기 발견 시장 전망 : 지역별, 금액(10억 달러)(2018-2030년)
제4장 북미의 다중 암 조기 발견 시장 전망(2018-2030년)
제5장 유럽의 다중 암 조기 발견 시장 전망(2018-2030년)
제6장 아시아태평양의 다중 암 조기 발견 시장 전망(2018-2030년)
제7장 라틴아메리카의 다중 암 조기 발견 시장 전망(2018-2030년)
제8장 중동 및 아프리카의 다중 암 조기 발견 시장 전망(2018-2030년)
제9장 경쟁 구도
능력 및 용도의 히트 맵
제조업체 및 용도의 히트 맵
기업의 시장 점유율 분석(2022년)
경쟁력 대시보드
기업 프로파일
Grail, LLC
Illumina, Inc.
Exact Sciences Corporation
Foundation Medicine
AnchorDx
Guardant Health, Inc.
Burning Rock Biotech Limited
GENECAST
Laboratory for Advanced Medicine, Inc
Singlera Genomics Inc
Elypta
Prenetics Global Limited(Prenetics)
Oncocyte Corporation
Micronoma Inc
EarlyDiagnostics, Inc
제10장 부록
AJY
영문 목차
영문목차
The global multi-cancer early detection (MCED) market is on the verge of substantial expansion, with Fairfield Market Research projecting a notable CAGR of 16.3% between 2023 and 2030. The market, which reached a valuation of approximately $0.89 billion in 2022, is anticipated to soar to around $2.5 billion by the end of 2030.
Key Market Trends
1. Rising Incidence of Cancer and Government Emphasis: The MCED market is set to expand due to factors such as the increasing incidence of cancer and government initiatives focusing on early cancer detection.
2. Development of Precise Tests: The development of tests that can precisely and simultaneously search for signs of various cancers is projected to fuel market growth. These tests address the lack of efficient screening approaches for many types of cancer.
3. Growing Awareness: Increased awareness of the benefits of early cancer detection for enhancing patient survival and lowering treatment costs is driving market potential.
4. Gene Panels Dominate: In 2022, the gene panel category dominated the MCED market. Gene panels enable precise risk assessment and early detection by offering targeted studies of multiple genes associated with various malignancies.
Key Growth Determinants
Exploding Cancer Prevalence: The growing prevalence of cancer is a major driver of market demand. Chronic diseases like cancer disproportionately affect the elderly population, particularly in high-income countries. The market is expected to rise as the elderly population increases.
Awareness Initiatives: Rising government initiatives to increase public awareness of the benefits of early diagnosis will drive market growth for MCED. These initiatives aim to educate people about the need for early diagnosis, leading to increased demand for multi-cancer screening tests.
Benefits of Early Detection: Early cancer detection results in better treatment outcomes, lower healthcare expenditures, and higher patient survival rates. Prompt intervention and specialized therapy made possible by early diagnosis lead to better patient outcomes, encouraging investment in MCED technologies.
Major Barriers
High Diagnostic System Costs: High costs of diagnostic devices, stringent regulatory regulations, and lengthy clearance processes for new launches hinder global MCED market growth.
Adoption of Refurbished Imaging Systems: Hospitals in poorer countries, unable to invest in new diagnostic imaging technology, often opt for refurbished systems. These systems are more affordable than new ones, impacting market growth.
Regional Highlights
Europe Leads in Revenue Contribution: Europe's dominance is due to rising cancer incidence and increased investment in research and development. The region's expanding population, vulnerability to chronic diseases, and economic diagnosis in rural areas support market expansion.
North America Shows Fastest Growth: North America is expected to experience the fastest growth due to government and market participant activities. The region's expanding cancer incidence and significant trials further boost market growth.
Competitive Landscape Analysis
The global MCED market is consolidated, with a few significant companies operating worldwide. Major firms are launching new products and expanding their distribution networks to increase their global presence. Market consolidation is expected to continue in the coming years.
Leaders in Global Multi-Cancer Early Detection Space
1. Grail, Llc
2. Illumina, Inc.
3. Exact Sciences Corporation
4. Foundation Medicine, Inc.
5. AnchorDx
6. Guardant Health, Inc.
7. Burning Rock Biotech Limited
8. GENECAST
9. Laboratory for Advanced Medicine, Inc.
10. Singlera Genomics Inc.
11. Elypta
12. Prenetics Global Limited (Prenetics)
13. Oncocyte Corporation
14. Micronoma Inc.
15. EarlyDiagnostics, Inc.
Global Multi Cancer Early Detection Market is Segmented as Below:
By Type:
Liquid Biopsy
Gene Panel
LDT
Others
By End User:
Hospitals
Diagnostic Laboratories
Others
By Geographic Coverage:
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Turkey
Russia
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Middle East & Africa
GCC
South Africa
Egypt
Nigeria
Rest of Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Multi Cancer Early Detection Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Multi Cancer Early Detection Market Outlook, 2018 - 2030
3.1. Global Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Liquid Biopsy
3.1.1.2. Gene Panel
3.1.1.3. LDT
3.1.1.4. Others
3.2. Global Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Hospitals
3.2.1.2. Diagnostic Laboratories
3.2.1.3. Others
3.3. Global Multi Cancer Early Detection Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Multi Cancer Early Detection Market Outlook, 2018 - 2030
4.1. North America Multi Cancer Early Detection Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Liquid Biopsy
4.1.1.2. Gene Panel
4.1.1.3. LDT
4.1.1.4. Others
4.2. North America Multi Cancer Early Detection Market Outlook, by End Use, Value (US$ Bn), 2018 - 2030
